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1  | INTRODUC TION
Black kidney transplant recipients have had inferior allograft survival 
that continues in the modern era of kidney transplantation.1-3 This 
difference is, in part, related to access to transplantation, with dis-
crepancies in living donor rates and dialysis vintage,4 delays in listing 
for transplantation,5 greater rates of deceased and marginal donor 
kidneys,6,7 and less favorable HLA matching.8 Such discrepancies 
contribute to a greater rate of AR in black recipients which impacts 
upon allograft survival.2
The prognosis for kidney survival after AR appears to vary depend-
ing on the timing of the rejection episode. Late AR is typically defined 
in the literature as occurring after the first 90 day post- transplantation 
and has been shown to have a greater negative impact on graft sur-
vival.9-12 One registry analysis showed similar outcomes in blacks in 
the early post- transplant period, but greater rates of late AR and late 
allograft failure in blacks.13 Immunosuppressive status, including early 
steroid withdrawal (ESW), was not analyzed in that study.
Because of greater rates of AR in blacks, ESW in this subgroup 
has remained controversial. The Astellas Corticosteroid Withdrawal 
Study showed a similar rate of biopsy proven rejection in blacks with 
and without ESW,14 but there were trends in greater chronic changes 
in blacks after ESW. A recent analysis of data from the United Network 
of Organ Sharing (UNOS) showed no increase in AR or allograft loss 
in a subset of black recipients who underwent ESW,15 providing that 
patients were carefully selected and received depleting antibody in-
duction therapy with tacrolimus and mycophenolate mofetil therapy. 
In the study herein, we observed that black recipients had compara-
ble rates of early AR but greater rates of late AR, consistent with reg-
istry data. We sought to further determine whether ESW influenced 
the higher rate of late AR seen in black recipients, and to analyze the 
impact of early and late AR, black race, and ESW on allograft survival.
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Abstract
Black kidney transplant recipients have more acute rejection (AR) and inferior graft 
survival. We sought to determine whether early steroid withdrawal (ESW) had an 
impact on AR and death- censored graft loss (DCGL) in blacks. From 2006 to 2012, 
AR and graft survival were analyzed in 483 kidney recipients (208 black and 275 non- 
black). Rates of ESW were similar between blacks (65%) and non- blacks (67%). AR 
was	defined	as	early	(≤3	months)	or	late	(>3	months).	The	impact	of	black	race,	early	
AR, and late AR on death- censored graft failure was analyzed using univariate and 
multivariate Cox models. Blacks had greater dialysis vintage, more deceased donor 
transplants, and less HLA matching, yet rates of early AR were comparable between 
blacks and non- blacks. However, black race was a risk factor for late AR (HR: 3.48 
(95% CI: 1.87- 6.47)) Blacks had a greater rate of DCGL, partially driven by late AR (HR 
with late AR: 5.6; 95% CI: 3.3- 9.3). ESW had no significant interaction with black race 
for risk of early AR, late AR, or DCGL. Independent of ESW, black kidney recipients 
had a higher rate of late AR after kidney transplantation. Late AR was highly predic-
tive of DCGL and contributed to inferior graft survival in blacks.
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2  | METHODS
2.1 | Study cohort and immunosuppression
A retrospective analysis of transplant recipients at University 
Hospitals Cleveland Medical Center was conducted following 
Institutional	 Review	 Board	 approval.	 Between	 January,	 2006	 and	
December, 2012, 500 consecutive patients received solitary kidney 
transplants. Patients were identified as black or non- black based 
on description in the demographic section of the medical records. 
For the purposes of this study, non- black included all other races 
and ethnicities. All patients received induction therapy with either 
20 mg of basiliximab on postoperative days 0 and 4 or antithymo-
cyte globulin (ATG) at a cumulative dosage of 6 mg/kg. Per our 
center protocol, all deceased donor (DD) kidney recipients received 
ATG, whereas living donor recipients, who were older than 50 years, 
received basiliximab. All patients were treated with oral tacrolimus 
therapy, typically starting within 24 hours of transplantation, with a 
target level of 8- 12 ng/mL in the first 3 months, followed by a target 
of 5- 8 ng/mL after 3 months. All patients also received antiprolifera-
tive therapy with mycophenolic acid derivatives. Intravenous meth-
ylprednisolone was administered at a 250 mg dose in the operating 
room, followed by 60 mg twice daily for 4 days. After postoperative 
day 4, ESW was undertaken in 65% of patients overall. Primary rea-
sons for not withdrawing steroids in the remaining cohort included 
delayed graft function (DGF) in 43%, high antibody sensitization 
with	a	panel	reactive	antibody	(PRA)	class	I	or	II	of	≥80%	at	the	time	
of transplant in 20%, and prior kidney transplantation in 28%.
2.2 | Acute rejection
Acute rejection episodes were identified by biopsy for cause and 
treated with pulse dose corticosteroids or ATG therapy for cel-
lular rejection, or in cases of antibody- mediated rejection (AMR), 
with corticosteroids, plasmapheresis, intravenous immunoglobu-
lin, and/or bortezomib. As in previous studies,9,12,16 early AR was 
defined as occurring within 3 months of transplantation and late 
AR after 3 months. Data were recorded on the presence of acute/
active AMR on biopsy based on BANFF criteria contemporary to 
the biopsy, along with the presence of donor- specific antibodies 
present in circulation and with either positive peritubular capil-
lary C4d staining diffusely by immunofluorescence or the pres-
ence of peritubular capillaritis.17 Nonadherence was evaluated and 
recorded if patients were described as nonadherent by the clini-
cal transplant nephrologists or nurse coordinators in the patient 
medical record.
2.3 | Statistical analyses
Values are shown as mean ± SD, median, or percentage. Comparisons 
for baseline variables were made between black and non- black re-
cipients. Comparisons were performed using a t test for continuous 
variables and a Pearson chi- square test for dichotomous variables. 
Additional variables examined included recipient factors (age, gen-
der, diabetes, dialysis vintage, prior transplant, PRA), transplant, 
and donor factors (donor source, donor age, HLA mismatch, DGF, 
induction immunosuppression, and ESW). We assessed association 
of black race with early AR, and late AR using Cox regression mod-
els. To assess interaction between black race and ESW, we fit Cox 
regression models with an interaction term with black race. In ad-
dition, since blacks and non- blacks were different in other baseline 
variables, we included variables whose P- values were <0.2 in multi-
variable models.
To compare time from date of transplant to acute rejection (either 
early or late) between blacks and non- blacks, we fit Kaplan- Meier 
curves to rejection- free survival and used log- rank test to compare 
both distributions. Patients were censored at time of death, last fol-
low- up date, or November 30, 2015, which was the end of the study 
period. For time to death- censored graft loss (DCGL), patients were 
again censored at time of death, last follow- up date, or November 
30, 2015. Kaplan- Meier survival curves were generated with time to 
DCGL, stratified by black race vs. non- black race. Log- rank test was 
used to compare the survival distributions of DCGL between blacks 
and non- blacks. Since early AR and late AR occurred during the fol-
low- up period, these variables were considered as time- varying co-
variates in survival analyses. Extended Kaplan- Meier curves using 
Snappin method were generated to examine time to DCGL, strati-
fied by early AR vs. no early AR, and late AR vs. no late AR. To exam-
ine the effect of black race on DCGL, we fit Cox regression models. 
To examine the effect of early AR and late AR on DCGL, we fit ex-
tended Cox regression models with these predictors as time- varying 
covariates. All analyses were performed using R.3.5.1®.
TABLE  1 Baseline characteristics of kidney transplant recipients 
(n = 483)
Blacks (208) Non- blacks (275) P- value
Age at 
transplant
48.3 (12) 50.5 (13.6) 0.1
Female 78 (37.5) 109 (39.6) 0.7
Dialysis vintage 
(mo)
65.8 (39.1) 28.2 (33.2) <0.001
Baseline 
diabetes
70 (33.7) 82 (29.8) 0.4
Prior 
transplant
18 (8.7) 38 (13.8) 0.1
Deceased 
donor
177 (85.1) 131 (47.6) <0.001
Donor age 43.3 (15.4) 43.9 (13.3) 0.7
HLA mismatch 4.51 (1.46) 3.60 (1.92) <0.001
Class I PRA 17. (30.7) 12.5 (25.2) 0.1
Class II PRA 9.0 (23.1) 10.1 (25.2) 0.6
ATG induction 179 (86.1) 152 (55.3) <0.001
Delayed graft 
function
34 (16.3) 50 (18.2) 0.7
Early steroid 
withdrawal
135 (64.9) 185 (67.3) 0.7
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3  | RESULTS
A total cohort of 500 patients received solitary kidney transplants 
during the study period. Seventeen patients with primary nonfunc-
tion or early death (<30 days) were excluded from analysis. Baseline 
characteristics are shown in Table 1. Blacks made up 43% of the 
cohort overall. Compared to non- blacks, blacks had longer dialysis 
vintage, a higher rate of deceased donor transplant, greater HLA 
mismatching, and a higher rate of ATG induction therapy. Rates of 
ESW were similar between non- blacks (67%) and blacks (65%).
3.1 | Early acute rejection
Forty- eight patients (9.9%) among the remaining cohort of 487 pa-
tients experienced early AR in the first 3 months of kidney trans-
plant. Of these, 19 (9.1%) occurred in blacks and 29 (10.5%) occurred 
in non- blacks (OR for black vs. non- black: 0.86 (95% CI: 0.48- 1.54)). 
ESW was associated with a 38% higher risk of early AR, but this was 
not statistically significant (HR: 1.38 (95% CI: 0.73- 2.61)). Also, there 
was no significant interaction between black race and ESW. In a mul-
tivariable model, after adjusting for other variables, black race was 
not significantly associated with early AR (Table 2).
3.2 | Late acute rejection
Forty- nine patients (10.1%) among the whole cohort experienced 
late AR after the first 3 months of kidney transplant. Of these, 35 
(16.8%) occurred in blacks and 14 (5.1%) occurred in non- blacks. 
Black race was associated with a fourfold increase in risk of late AR, 
and this was statistically significant (HR: 3.48 (95% CI: 1.87- 6.47)). 
ESW was associated with a 28% less likelihood of late AR but this 
was not statistically significant (HR: 0.72 (95% CI: 0.40- 1.28)). As 
with early AR, there was no significant interaction between black 
race and ESW for risk of late AR. In a multivariable model, after ad-
justing for other variables, black race was significantly associated 
with late AR (Table 2).
Figure 1 illustrates Kaplan- Meier curves for freedom from rejec-
tion (both early AR and late AR) survival, stratified by black race. 
Blacks had higher rates of late AR at all time points, with a nota-
ble increase after 2 year post- transplantation. We also explored 
rates of AMR. Not surprisingly, AMR on biopsy was more common 
in late AR, occurring in 33% of cases compared to 8% of early AR 
(P = 0.003). AMR occurred in 29% of blacks with late AR vs. 43% 
of non- blacks with AMR (P = 0.13). In patients with early AR, five 
patients (10%) were described as nonadherent, including two pa-
tients who displayed nonadherence after the early AR episode. 
Alternatively, twelve patients (24%) were deemed nonadherent in 
the late AR cohort (P = 0.07 vs early AR). Black patients with late AR 
had documented nonadherence in 29% of cases vs. 14% of cases in 
non- blacks (P = 0.30).
3.3 | Graft survival
A total of 117 out of 483 (24%) patients in the cohort had overall 
graft failure (including death with function) during a mean follow- up 
of 5 years 3 months. Overall graft survival was 97% at 1 year, 80% 
at 5 years, and 65% at 10 years. Since we were interested in inter-
action between ESW and black race, and ESW would mainly affect 
death- censored graft survival (DCGS), we focused on DCGS for fur-
ther analysis.
A total of 72 out of 483 (15%) patients in the cohort had DCGL 
during a mean follow- up of 5 years 3 months. DCGS was 99% at 
1 year, 87% at 5 years, and 78% at 10 years. Figure 2 illustrates 
Kaplan- Meier survival curves for DCGS, stratified by black race vs. 
non- blacks. DCGS was 99% at 1 year, 84% at 5 years, and 67% at 
10 years for blacks compared with 98% at 1 year, 88% at 5 years, 
and 86% at 10 years for non- blacks (P- value = 0.01). Black race was 
TABLE  2 Hazard ratios for early and late AR by black race
Model Early AR Late AR
Black race, unadjusted 0.86 (0.48- 1.54) 3.48 (1.87- 6.47)
Black race, adjusted for 
Steroid withdrawal
0.87 (0.49- 1.55) 3.44 (1.96- 7.19)
Black race, adjusted for 
othersa
0.89 (0.44- 1.78) 2.28 (1.10- 5.41)
aAdjusted for steroid withdrawal, age at transplant, dialysis vintage, 
donor source, class I flow PRA, ATG induction, HLA mismatch. 
F IGURE  1 Kaplan Meier curves for rejection- free survival, 
stratified by black race
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associated with a 91% higher likelihood of DCGL (HR: 1.91; 95% 
CI: 1.19- 3.05). Black race remained a risk factor for DCGL after ad-
justment for ESW (HR: 1.84; 95% CI: 1.15- 2.95). Figure 3 illustrates 
Kaplan- Meier survival curves for DCGS, stratified by early AR. Early 
AR was associated with a 2.3- fold increased risk of DCGL (HR: 2.3; 
95% CI: 1.4- 3.9). Figure 4 illustrates Kaplan- Meier survival curves for 
DCGS, stratified by late AR. Late AR was much stronger risk factor 
for DCGL than early AR (HR: 5.6; 95% CI: 3.3- 9.3). In the multivari-
able Cox model after adjustment for early AR, hazard of black race 
for DCGL was 1.9 (95% CI: 1.2- 2.9). In the multivariate Cox model 
after adjustment for late AR, hazard ratio of black race for DCGL was 
1.8 (95% CI: 1.1- 2.7). However, after adjustment for other variables, 
black race was no longer a significant risk factor for DCGL (Table 3).
4  | DISCUSSION
In this analysis of long- term outcomes in a large cohort of kidney 
transplant recipients with ESW, we examined outcomes related to 
early and late AR and allograft survival in black vs. non- black re-
cipients. Blacks were disadvantaged, with higher rates of deceased 
donor transplants, longer dialysis vintage, and greater HLA mismatch-
ing. Despite these differences, early AR rates were similar between 
blacks and non- blacks. There was a higher rate of ATG induction in 
black recipients, which may have contributed to comparable early 
AR rates in black recipients. ATG may be protective particularly in 
patients undergoing ESW. The Astellas Corticosteroid Withdrawal 
Study showed a trend for less rejection after ESW in patients who 
received ATG compared to basiliximab,14 and a recent UNOS registry 
analysis showed a benefit in allograft survival with ATG specifically 
in ESW patients.18
We found an overrepresentation of black recipients with late 
AR compared with non- blacks. Rates appeared higher at all time 
points, with a spike in AR after 2 year post- transplantation in blacks. 
Late AR conveyed an approximately 5- fold increase in the rate of 
DCGL. It is likely that late AR is a major factor contributing to the 
well- described discrepancies in allograft survival between blacks 
and non- blacks.19-21 A previous analysis of UNOS data compared 
outcomes between black and non- black recipients of paired DD kid-
neys.13 Black recipients in that analysis were actually shown to have 
superior overall early survival at 6 months in a multivariable model. 
However, there was a divergence in allograft survival beyond 1 year, 
with greater graft loss in blacks over time, and this late graft loss 
appeared to be driven by late AR.
ESW has been commonly employed in the modern transplant 
era, with the goal of reducing the long- term morbidity associated 
with steroid regimens. As this study is retrospective, patients 
were not randomized to ESW; higher risk patients with DGF, prior 
transplant, or high antibody sensitization were maintained on ste-
roid therapy in our cohort. However, rates of ESW were similar in 
F IGURE  2 Kaplan Meier survival curves for death- censored 
graft survival (DCGS), stratified by black race
F IGURE  3 Kaplan Meier survival curves for death- censored 
graft survival (DCGS), stratified by early AR
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blacks and non- blacks. We found that ESW was associated with 
a trend for greater risk of early AR, but not late AR. Gaber and 
colleagues reported on a follow- up of the Astellas Corticosteroid 
Withdrawal Study and, after including cases of borderline rejec-
tion, identified a greater rate of early AR in ESW patients, similar 
to our findings.22 Interestingly, they found that late AR (beyond 
2 years) in blacks was higher in steroid maintenance patients. 
We also found that ESW did not contribute to late AR in blacks. 
On the contrary, the highest rate of late AR was seen in blacks 
who maintained corticosteroid therapy. Black patients with ste-
roid maintenance may have been identified early on as higher 
risk based on demographic or socioeconomic factors, which may 
explain this finding. Regardless, based on our ESW protocol, ESW 
did not appear to contribute to inferior outcomes seen in black 
recipients.
Other studies have identified late AR as a factor contributing 
to worse outcomes and lower rates of graft survival compared 
with early AR. Sijpkens et al found a marked decreased in long- 
term allograft survival associated with late AR, similar to our find-
ings.12 In our study, we identified AMR in one- third of patients 
with late AR, with a greater than fourfold rate compared with 
early AR. This likely contributed to the high rate of allograft loss, 
as late AMR responds poorly to current therapy.9,23 In other stud-
ies, late AMR was previously found to be associated with younger 
age, suboptimal immunosuppression, and nonadherence to med-
ical therapy.9
Nonadherence contributed to late AR in approximately one 
quarter of cases, with a trend for higher rates of nonadherence 
in blacks in our analysis. At later time points after transplanta-
tion, patients typically have less frequent follow- up and labora-
tory testing and may have variable rates of follow- up. Patients 
may also develop financial challenges in paying for medications 
over time.24 It is likely that socioeconomic factors play a role in 
the differences in late outcomes in black kidney recipients, as less 
education and lower rates of private insurance have been found to 
persist in blacks in the modern transplant era.1 As a result of the 
findings herein, we advocate for close patient monitoring, even 
years after transplantation, particularly in patients at higher risk 
of late AR. We did not analyze trough levels of tacrolimus in this 
cohort, but there may be a need for maintenance of higher targets 
above 5- 8 ng/mL in higher risk patients as well. Variability in levels 
of tacrolimus has been shown to contribute to late AR and graft 
loss.25,26
This study has limitations. The study is retrospective, resulting 
in a selection bias for which patients are in the ESW group; patients 
were selected for ESW based on perceived risk and definite criteria, 
although black race was not considered an indication for avoidance 
of ESW. Analysis of AMR was also limited and descriptive in nature. 
Furthermore, nonadherence is very difficult to measure27,28 and re-
lied on subjective interpretation of healthcare providers, which may 
be influenced by unconscious bias.
In conclusion, we demonstrate that inferior outcomes in blacks 
are driven by late outcomes, including late AR, and show that such 
late outcomes do not appear to be related to ESW. Solving the di-
lemma of heightened late AR in blacks may not rely on corticosteroid 
dosing, but rather on a multipronged approach of improved immu-
nological monitoring, graft follow- up, and assessment of adherence 
late after transplantation, tailored to the individual patient’s bio-
logical and socioeconomic characteristics. Prospective studies are 
needed to determine to what degree disparate late outcomes for 
black patients are driven by biologic or socioeconomic factors.
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graft survival (DCGS), stratified by late AR





Black race, unadjusted 1.91 (1.19- 3.05)
Black race, adjusted for steroid withdrawal 1.84 (1.15- 2.95)
Black race, adjusted for othersa 1.36 (0.78- 2.38)
Black race, adjusted for early AR 1.89 (1.24- 2.89)
Black race, adjusted for late AR 1.77 (1.14- 2.74)
aAdjusted for steroid withdrawal, age at transplant, dialysis vintage, 
donor source, class I flow PRA, ATG induction, HLA mismatch.
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